The effects of control of systolic and diastolic hypertension on cardiovascular and all-cause mortality in a community-based population cohort

Journal of Human Hypertension

Volumn 27, Issue 11, 2013, Pages 693-697

  Barengo, N C ^a,b,c   Antikainen, R ^a   Kastarinen, M ^a,d   Laatikainen, T ^e,f   Tuomilehto, J ^g,h  

^a UNIVERSITY OF OULU   (Finland)

^b Fundacion para Prevencion Control Enfermedades Cronicas No Transmisibles America Latina (FunPRECAL)   (Argentina)

^c Subdirección de las Enfermedades No Transmisibles   (Colombia)

^d Finnish Medicines Agency   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^h DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

all cause mortality; cardiovascular disease; control; diastolic blood pressure; mortality; systolic blood pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ALL CAUSE MORTALITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAUSE OF DEATH; CROSS-SECTIONAL STUDIES; DIASTOLE; FEMALE; FINLAND; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SYSTOLE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885579342     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.22     Document Type: Article

References (36)

1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke and coronary heart disease. Part 2: short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-839.
2. Boudik F, Reissigova J, Hrach K, Tomeckova M, Bultas J, Anger Z et al. Primary prevention of coronary artery disease among middle aged men in Prague: twenty-year follow-up results. Atherosclerosis 2006; 184: 86-93.
3. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006; 24: 423-430.
4. Dahlö f B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
5. Nielsen WB, Vestbo J, Jensen GB. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens 1995; 9: 175-180.
6. Antikainen R, Jousilahti P, Tuomilehto J. Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population. J Hypertens 1998; 16: 577-583.
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
8. Ikeda A, Iso H, Yamagishi K, Inoue M, Tsugane S. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC Study. Am J Hypertens 2009; 22: 273-280.
9. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761-767.
10. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-745.
11. Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease in treated hypertension-a prospective cohort study over three decades. J Intern Med 2005; 257: 496-502.
12. Wilhelmsen L, Berglund G, Elmfeldt D. The multifactor primary prevention trial in Gö teborg, Sweden. Eur Heart J 1986; 7: 279-288.
13. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. Br Med J 1998; 317: 167-171.
14. Clausen J, Jensen G. Blood pressure and mortality: an epidemiological survey with
15. years follow-up. J Hum Hypertens 1992; 6: 53-59.
16. Barengo NC, Kastarinen M, Antikainen R, Nissinen A, Tuomilehto J. The effects of awareness and control of hypertension on cardiovascular and all-cause mortality in a community-based population. J Hum Hypertens 2009; 23: 808-816.
17. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
18. Casiglia E, Mazza A, Tikhonoff V, Pessina AC. Population-based studies improve outcome in hypertensive patients. Am J Hypertens 2002; 15: 605-608.
19. Trafford JA, Horn CR, O'Neal H, McGonigle R, Halford-Maw L, Evans R. Five year follow-up of effects of treatment of mild and moderate hypertension. Br Med J (Clin Res Ed) 1981; 282: 1111-1113.
20. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002; 162: 577-581.
21. Harms LM, Schellevis FG, van Eijk JT, Donker AJ, Bouter LM. Cardiovascular morbidity and mortality among hypertensive patients in general practice: the evaluation of long-term systematic management. J Clin Epidemiol 1997; 50: 779-786.
22. Gudmundsson LS, Johannsson M, Thorgeirsson G, Sigfusson N, Sigvaldason H, Witteman JC. Hypertension control as predictor of mortality in treated men and women, followed for up to 30 years. Cardiovasc Drugs Ther 2005; 19: 227-235.
23. Bulpitt CJ, Palmer AJ, Fletcher AE, Beevers DG, Coles EC, Ledingham JG et al. Optimal blood pressure control in treated hypertensive patients. Report from the Department of Health Hypertension Care Computing Project (DHCCP). Circulation 1994; 90: 225-233.
24. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P. Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol 2000; 29: 49-56.
25. Tunstall-Pedoe H, for the WHO MONICA Project. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988; 41: 105-114.
26. Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J. Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care 2005; 28: 799-805.
27. Hu G, Tuomilehto J, Silventoinen K, Barengo NC, Jousilahti P. The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47 212 middle-aged Finnish men and women. Int J Obes Relat Metab Disord 2005; 29: 894-902.
28. Vartiainen E, Laatikainen T, Salomaa V, Jousilahti P, Peltonen M, Puska P. Sydäninfarkti-ja aivohalvausriskin arviointi FINRISKI-tutkimuksessa (The FINRISK FUNCTION: Estimation of the risk of coronary events and stroke in the Finnish population). Suomen Lääkärilehti 2007; 48: 4507-4513.
29. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-3264.
30. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH et al. for Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
31. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
32. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85: 251-255.
33. Ong KL, Cheung BMY, Man CY, Lau CP, Lam KSL. Prevalence, awareness, treatment and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75.
34. Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A et al. Prevalence, awareness and treatment of hypertension in Finland during 1982-2007. J Hypertens 2009; 27: 1552-1559.
35. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
36. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 2006; 19: 243-250.